R&D channel feed – Endpoints News

R&D channel feed

A radically inexpensive, non-profit approach can transform drug R&D? Now, wait a minute…

9 years ago

Amid layoff fears, AstraZeneca stakes a ‘For Sale’ sign on US campus

9 years ago

Sofinnova Ventures ups the ante - again - as it closes in on $650M biotech fund

9 years ago

Protocols: BeiGene signs up Medivation’s Amy Peterson as its new CMO; Acne drug developer files for $60M IPO

9 years ago

Novartis heralds a PhIII success for secondary progressive MS drug

9 years ago

That big new hyperparathyroidism drug from Amgen? The FDA rejected it

9 years ago

Biotech has a bad day after politicos pounce on another drug pricing scandal

9 years ago

Under the gun, Nymox sparks another rally with a new batch of follow-up BPH data

9 years ago

Meet Ike, the drug test subject that lived to be 140

9 years ago

Still in spotlight of a federal probe, Insys touts PhIII pain study as it preps an NDA

9 years ago

AstraZeneca sells off more assets from its island of misfit drugs in $1.6B Pfizer deal

9 years ago

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

9 years ago

Gilead tackles a big PhIII program for blockbuster hopeful filgotinib

9 years ago

Tokai retreats from the clinic after lead drug implodes in PhIII

9 years ago

Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D

9 years ago

Little Stemline grabs a big ‘breakthrough’ title for its pivotal-stage cancer drug

9 years ago

Sanofi can’t even buy a break now, as rival Novo speeds ahead on diabetes showdown

9 years ago

Axel Bouchon starts signing players for a new league of game-changing biotechs

9 years ago

Pfizer bags Medivation buyout with blowout $14B cash offer

9 years ago

Golden Triangle gets £75M in fresh venture funds for Cambridge U spinouts

9 years ago

Welcome Casebia, the $335M gene editing JV hatched by Bayer and CRISPR Therapeutics

9 years ago

Following another PhII failure, cash-strapped Cerulean chops half its staff

9 years ago

Protocols: Mallinckrodt lands a new corporate campus in NJ; Nutrinia bags a $30M round for oral insulin

9 years ago

Auris shares are crushed as tinnitus drug fails PhIII test

9 years ago

First page Previous page 321 322 323324325 326 327 Next page Last page